Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1A1 | P14550 | 16/20 | 0.53 |
| ▸ | AKR1B1 | P15121 | 16/20 | 0.53 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9671730 | 0.94 | AKR1A1 (0.48) | AKR1A1AKR1B1ITGA4 | |
| SCHEMBL1201500 | 0.88 | AKR1A1 (0.66) | AKR1A1AKR1B1 | |
| SCHEMBL9674175 | 0.79 | AKR1A1 (0.60) | AKR1A1AKR1B1ITGA4 | |
| SCHEMBL23178937 | 0.75 | AKR1B1 (0.56) | AKR1A1AKR1B1 | |
| SCHEMBL9672265 | 0.75 | AKR1B1 (0.51) | AKR1A1AKR1B1ITGA4 | |
| SCHEMBL25892758 | 0.73 | AKR1A1 (0.69) | AKR1A1AKR1B1ITGA4 | |
| SCHEMBL9672199 | 0.71 | AKR1A1 (0.71) | AKR1A1AKR1B1 | |
| SCHEMBL9674037 | 0.71 | AKR1B1 (0.48) | AKR1A1AKR1B1ITGA4 | |
| SCHEMBL9672184 | 0.70 | AKR1B1 (0.46) | AKR1A1AKR1B1ITGA4 | |
| SCHEMBL20845828 | 0.70 | AKR1A1 (0.72) | AKR1A1AKR1B1ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060058310-A1 | Remedies for vertebral canal stenosis | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-03-16 | — | — | US | claimed |
| US-20060058310-A1 | Remedies for vertebral canal stenosis | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058310-A1 | Remedies for vertebral canal stenosis | ALDOA, AKR1B1, AKR1A1 | AKR1A1 3/4885AKR1B1 2/4885ITGA4 3899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.